Randomized, Proof-Of-Concept Trial of Low Dose Naltrexone for Patients with Breakthrough Symptoms of Major Depressive Disorder on Antidepressants

Abstract Background Given the proposed dopaminergic mechanism of low-dose naltrexone (LDN), we examined its efficacy as augmentation for depressive breakthrough on pro-dopaminergic antidepressant regimens. Methods 12 adults (67% female, mean age = 45 ± 12) with recurrent DSM-IV major depressive diso...

Ausführliche Beschreibung